[1]付瑞枫,茅宁莹.“双通道”背景下国谈创新药零售终端流通现状[J].卫生经济研究,2023,40(2):24-27,33.
　FU Ruifeng,MAO Ningying.Analysis on the Circulation and Obstacles of Innovative Drugs in Retail Terminal under the Dual-channel Policy in China[J].Journal Press of Health Economics Research,2023,40(2):24-27,33.
点击复制

“双通道”背景下国谈创新药零售终端流通现状
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
40
期数:
2023年2期
页码:
24-27,33
栏目:
药械管理
出版日期:
2023-02-01

文章信息/Info

Title:
Analysis on the Circulation and Obstacles of Innovative Drugs in Retail Terminal under the Dual-channel Policy in China
作者:
付瑞枫1; 茅宁莹1
1.中国药科大学国际医药商学院，江苏 南京 211198
Author(s):
FU Ruifeng;  MAO Ningying
School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing Jiangsu 211198, China
关键词:
双通道政策; 零售药房; 创新药; 流通障碍
Keywords:
dual-channel policy;  retail pharmacy;  innovative drug;  circulation obstacle
分类号:
R95
文献标志码:
A
摘要:
目的：“双通道”背景下，分析国谈创新药在零售终端的流通现状，提出促进创新药流通的建议。方法：基于利益相关者视角，分析国谈创新药零售终端流通中不同主体的冲突源，厘清国谈创新药院外流通障碍及成因。结果：“双通道”政策总体上有助于提高国谈创新药的可及性，但在零售终端流通过程中面临储备品种较少、各地配备情况差异较大、放量拉动效应不显著、患者满意度偏低等障碍；原因在于政府部门监管难和控费压力大且各地政策标准不一，医院对处方外流意愿不强，零售药房面临“高标准、低利润”的双重挑战以及创新药患者对零售药房能力要求高、信任程度低等。结论：各利益相关方从加速品种整合、提高处方流转动力与效率以及完善第三方健康服务体系入手，逐步探索构建协调机制，充分发挥零售药房的补充作用，提高创新药的可及性。
Abstract:
Objective To analyze the circulation and obstacles of state-negotiated innovative drugs in retail terminal under the dual-channel policy, and to propose corresponding countermeasures and suggestions to promote the accessibility of innovative drugs. Methods Based on the perspective of stakeholders, the stakeholder model was constructed. Analyzing the sources of conflicts among different subjects including government departments, hospitals, retail pharmacies, patients and so on, the causes of out-of-hospital circulation obstacles of innovative drugs were clarified. Results The dual-channel policy was generally helpful to improve the accessibility of innovative drugs, but it also faced obstacles in the process of retail distribution, such as insufficient reserve varieties, wide regional allocation differences, insignificant volume-pull effect, and low patient satisfaction. The obstacles lied in the difficulty of supervision and cost control pressure of government departments, different policy standards in various regions, weak prescription outflow from the hospital, the dual challenges of "high standards and low profits" faced by retail pharmacies, the high requirements and low trust of patients to retail pharmacies. Conclusion It is recommended that all stakeholders should explore the coordination mechanism, give full play to the supplementary role of retail pharmacies, and finally ensure the smooth accessibility of innovative drugs starting from three aspects: accelerating the integration of allocation varieties, improving the impetus and efficiency of prescription outflow and improving the third-party medical and health service system.

参考文献/References:

[1] 中央人民政府.74种新药进医保 谈判成功率再创新高[EB/OL].（2021-12-04）[2022-07-27].http://www.gov.cn/zhengce/2021-12/04/content_5655779.htm.
[2] 中央人民政府.关于建立完善国家医保谈判药品“双通道”管理机制的指导意见[EB/OL].（2021-05-10）[2022-07-27].http://www.nhsa.gov.cn/art/2021/5/10/art_37_5023.html.
[3] 陈永正，黄滢.我国专利药独家药价格谈判机制的战略问题[J].现代经济探讨，2017（6）：16-23.
[4] 创新药在两大终端的市场表现盘点[EB/OL].（2022-05-27）[2022-08-03]. https://new.qq.com/omn/20220527/20220527A0B NB400.html.
[5] 药房客流新常态下的危与机——中国零售药房购药者行为分析[EB/OL].（2022-06-01）[2022-08-03].http://industry.caijing.com.cn/20220601/4865302.shtml.
[6] 王苑如，谢金平，胡紫馨，等.加拿大抗肿瘤药品评审中利益相关者的作用及启示[J].中国药房，2022，33（9）：1031-1036.
[7] 湖北省医疗保障局.关于建立完善国家医保谈判药品 “双通道”管理机制 持续做好谈判药品落地工作的通知[EB/OL].[2021-10 -28]（2022-07-07）.http://ybj.hubei.gov.cn/zfxxgk/zc/gfwj/202110/t20211028_3831965.shtml.
[8] 四川启动特殊药品处方流转试点，157个药品纳入[EB/OL]. （2021-06-30）[2022-08-04].https://new.qq.com/omn/20210630/20210630A08ECC00.html.
[9] “双通道”出台半年零售药房的喜与忧[EB/OL].[2021-12-17]（2022-07-07）.https://mp.weixin.qq.com/s/9Hg6-kPd4FXWqzmD Mv3Uxw.
[10] 吴培,董晨东,茅宁莹.“互联网+”背景下处方外流推进障碍与对策分析——基于利益相关者视角[J].中国药房，2021，32（12）：1409-1415.
[11] “双通道”政策执行后特药零售表现大揭秘[EB/OL].[2022-04-24]（2022-07-07）.http://news.pharmnet.com.cn/news/2022/04/24/565840.html.
[12] 杨剑英.“双通道”品种的引流增效[J].中国药房，2022（3）：41-45.
[13] BCG.2022年医药零售行业研究报告[EB/OL].（2022-07-25）[2022 -07-29]. https://www.vzkoo.com/read/202207258c36106e57c3239 744134d0a.html.
[14] 国家医保局. 关于进一步做好基本医疗保险跨省异地就医直接结算工作的通知[EB/OL].（2022-07-26）[2022-08-02].http://www.nhsa.gov.cn/art/2022/7/26/art_104_8629.html.
[15] 杨剑英.不一样的“双通道”药房基建[J].中国药房，2022（3）：36-40.

更新日期/Last Update: 2023-02-01